Science and the New Zealand sector

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway, not a general licence to use cannabis. The legal route to access is a prescription from a medical practitioner, and the products dispensed must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The most common misunderstanding is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated products. In New Zealand, the legal product is a manufactured pharmaceutical; even dried flower, when prescribed, is dispensed through a pharmacy under the Medicinal Cannabis Scheme, not through a dispensary or retail outlet.

This page is the entry point to the four detailed guides in this section. It gives you the regulatory skeleton, the evidence landscape, the product categories, and the practical boundaries of the New Zealand scheme. The focused guides, on the patient pathway, the evidence, the products, and safety in daily life, each cover one part in depth.

---

What medicinal cannabis is (and is not) in New Zealand

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975, not a general licence to use cannabis. Since the Misuse of Drugs (Medicinal Cannabis) Amendment Act came into force in 2020, access has been legal only through a prescription from a medical practitioner. The product must be a manufactured pharmaceutical that meets Good Manufacturing Practice (GMP) standards and has been notified to the Ministry of Health under the Medicinal Cannabis Scheme.

The most common misconception is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated products. That is not the case. The legal product is a manufactured pharmaceutical. Even when the product is dried flower, it is prescribed, dispensed through a pharmacy, and supplied in a pharmaceutical-grade pack. The Medicinal Cannabis Agency (MCA), which sits within Medsafe, is the regulator that issues licences for cultivation, manufacture, supply, and prescribing under the scheme.

The Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the legal framework. Under the scheme, a medical practitioner can prescribe a CBD or THC product that meets GMP standards and is approved by the Ministry of Health. The scheme does not legalise smoking raw plant material, and it does not allow a person to grow their own plants for medical use. Products are dispensed through a pharmacy, not a dispensary or a retail shop. The New Zealand Ministry of Health (Medsafe) runs the Medicinal Cannabis Agency (MCA), which licenses cultivators, manufacturers, and suppliers, and maintains a public register of notified products. As of the 2020 amendments to the Misuse of Drugs Act, the scheme came into full effect, and the NZ Formulary lists cannabis products that can be prescribed. Personal decisions about a specific product or dose should be directed to a qualified prescriber or pharmacist.

KEY_SECTIONS: - What “medicinal cannabis” means in New Zealand law - How the prescription pathway works - What products exist and how to compare them - The evidence: what is known and what is not - Safety, side effects and daily life - Where to go next

DETAILED SECTIONS:

What “medicinal cannabis” means in New Zealand law

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The scheme legalises access via a prescription from a medical practitioner, and products must meet GMP standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

The legal framework

The Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, is administered by the Medicinal Cannabis Agency (MCA), a unit within Medsafe. The scheme allows medical practitioners to prescribe cannabis-based products that meet GMP standards and have been approved by the Ministry of Health. It does not legalise recreational use, nor does it allow a patient to grow, possess, or use raw plant material outside a prescription.

The scheme’s key legal point: a prescription is the only legal route. Products must be manufactured to Good Manufacturing Practice (GMP) standards and notified to the Ministry of Health before they can be prescribed. As of 2023, the Medicinal Cannabis Scheme in New Zealand is regulated under the Misuse of Drugs Act 1975, and the Ministry of Health’s Medicinal Cannabis Agency (MCA) issues licences for cultivation, manufacture, and supply.

What is medicinal cannabis?

Medicinal cannabis is a pharmaceutical product, not a herbal remedy. Under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, a medical practitioner can prescribe a cannabis-based product if they believe it is clinically appropriate. The product must be a “controlled drug” approved by Medsafe, and it must meet GMP (Good Manufacturing Practice) standards. This is the key legal boundary: the scheme does not legalise raw plant material for personal use; it legalises a prescription pathway for manufactured products.

How the New Zealand scheme works

The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. It is administered by the Medicinal Cannabis Agency (MCA), which sits within Medsafe, New Zealand’s medicines regulator. The scheme allows medical practitioners to prescribe cannabis-based products that meet GMP standards and have been approved by the Ministry of Health. The key point: a prescription from a medical practitioner is the only legal route to access these products. The raw flower, when prescribed, is dispensed through a pharmacy, not a dispensary, and patients cannot legally smoke it or buy it from unregulated sources.

PRESCRIPTION_PATHWAY: - The patient pathway begins with a consultation with a medical practitioner (GP or specialist) who can prescribe under the Misuse of Drugs Act. - The practitioner must consider the patient’s condition, previous treatments, and potential risks; they are not required to be a cannabis specialist, but they must be satisfied that conventional treatments have failed or are unsuitable. - The prescription is written for a specific product (e.g., Tilray 10:10 oil) with a dose and administration route; it is not a general “cannabis prescription”. - The prescription is dispensed at a licensed pharmacy, not a dispensary or retail outlet. - Under the Medicinal Cannabis Scheme (established 1 April 2020), products must meet GMP standards and be approved by the Ministry of Health; the scheme is administered by the Medicinal Cannabis Agency (MCA), part of Medsafe. - Patients cannot legally possess or use raw cannabis flower unless it is prescribed and dispensed through a pharmacy; the raw plant material is not a legal “herbal remedy”. - The NZ Formulary lists cannabis products with monographs; prescribers should follow the NZ Formulary guidance. - The Misuse of Drugs Act 1975 was amended in 2018 to allow medicinal use, and the Medicinal Cannabis Scheme was fully implemented in 2020 (Medicinal Cannabis Scheme, NZ Ministry of Health).

VERIFIED RESEARCH. This is the only factual source. Do not invent details: - The Medicinal Cannabis Scheme legalised access to medicinal cannabis products on 1 November 2020, under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and subsequent regulations. (NZ Ministry of Health) - Medsafe is the New Zealand Medicines and Medical Devices Safety Authority, and it runs the Medicinal Cannabis Agency (MCA) that licences and regulates the scheme. - Products must meet GMP standards and be approved by the Ministry of Health before they can be prescribed and dispensed. - The scheme does not allow smoking raw plant material; the only legal forms are manufactured pharmaceutical products (oils, capsules, dried flower for vaporisation, and some oromucosal sprays). - Prescriptions are issued by medical practitioners under the Misuse of Drugs Act; the patient pathway starts with a GP or specialist, not a shop or website. - The NZ Formulary lists medicinal cannabis products with prescribing guidance; it is maintained by the Pharmacology and Therapeutics Advisory Committee (PTAC) and published by the Ministry of Health. - Healthify (previously Health Navigator) is the official NZ health information resource; it includes patient-oriented summaries of medicinal cannabis and its risks. - New Zealand’s Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019) came into effect on 1 April 2020. It sets out who can prescribe, product standards (GMP), and the requirement for products to be approved by the Ministry of Health. - The Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (effective 18 December 2018) created the scheme and allowed doctors to prescribe cannabis products without needing Ministerial approval, moving it into the normal prescription pathway. - Under the scheme, a medical practitioner can prescribe medicinal cannabis products that meet GMP standards; the patient then takes the prescription to a licensed pharmacy. The raw flower is available but only as a prescribed pharmaceutical product, not for smoking. - The Medicinal Cannabis Agency (MCA), part of Medsafe, administers the scheme. It licenses companies to cultivate, manufacture, supply, or import controlled drugs for medicinal use. It does not approve individual prescriptions. - Medsafe approves finished products for sale in New Zealand under Section 29 of the Misuse of Drugs Act. Products must meet GMP and contain only approved active ingredients (THC, CBD, or both). - The NZ Formulary lists cannabis products with official monographs, and prescribers use it as the reference for dosing and product selection. - The Medicinal Cannabis Scheme legalised access from 1 November 2020 under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2019. Under the scheme, a medical practitioner can prescribe a CBD or THC product that meets GMP standards, and the Ministry of Health’s Medicinal Cannabis Agency licenses cultivators, manufacturers, and pharmacies. - Products available in New Zealand include: Tilray 10:10, Tilray 25:25, Medleaf THC25, Medleaf THC10:CBD10, Medleaf CBD100, NUBU 100 (CBD isolate oil), Cann Group THC20, Cann Group CBD100, Spectrum Red No. 1, Spectrum Yellow No. 2, LGP Classic 10:10 and 20:5, Helius THC25, Helius CBD100, MedReleaf Avidekel, Bedrocan, Bediol, Bedrolite, Cannabisol 100, Eve CBD flower, Aurora Sedaprem, Aurora Vespucci, Cann Group THC20, Cann Group CBD100, Tilray 10:10, Tilray 25:25, and others. - Not all products are available at all times; availability changes with supply and regulatory approval. Do not present this list as current stock. - Products are classified by the ratio of THC to CBD, not by brand strength. Patients should ask their prescriber for a product matching their symptom profile, not a brand.

UNIQUE_PAGE_GOAL: Give the reader a clear mental model of how medicinal cannabis in New Zealand actually works: the legal pathway, the product landscape, the evidence, and how to evaluate a product or a prescriber’s advice.